Compare CXM & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | RXRX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2021 |
| Metric | CXM | RXRX |
|---|---|---|
| Price | $6.24 | $3.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $8.28 | $7.50 |
| AVG Volume (30 Days) | 3.1M | ★ 14.1M |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $857,200,000.00 | $74,681,000.00 |
| Revenue This Year | $2.52 | $12.11 |
| Revenue Next Year | $4.94 | $82.52 |
| P/E Ratio | $347.50 | ★ N/A |
| Revenue Growth | 7.64 | ★ 26.92 |
| 52 Week Low | $4.72 | $2.77 |
| 52 Week High | $8.28 | $7.18 |
| Indicator | CXM | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 52.30 |
| Support Level | $4.99 | $2.87 |
| Resistance Level | $8.21 | $3.42 |
| Average True Range (ATR) | 0.36 | 0.18 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 3.11 | 64.81 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.